HEMODYNAMIC AND RENAL EFFECTS OF DOPEXAMINE AND DOBUTAMINE IN PATIENTS WITH REDUCED CARDIAC-OUTPUT FOLLOWING CORONARY-ARTERY BYPASS-GRAFTING

被引:29
作者
MACGREGOR, DA
BUTTERWORTH, JF
ZALOGA, GP
PRIELIPP, RC
JAMES, R
ROYSTER, RL
机构
[1] WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT ANESTHESIA,CARDIAC ANESTHESIA SECT,WINSTON SALEM,NC 27157
[2] WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT MED,PULM SECT SECT,WINSTON SALEM,NC 27157
关键词
CARDIAC SURGERY (CABG); DOBUTAMINE; DOPEXAMINE; INOTROPIC SUPPORT (INOTROPY);
D O I
10.1378/chest.106.3.835
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: Dopexamine hydrochloride is a novel synthetic adrenergic agonist that combines the renal effects of dopamine with the hemodynamic effects of dobutatmine. Our study is designed to compare the hemodynamic, diuretic, and natriuretic effects of dopexamine and dobutamine in patients with reduced cardiac index following heart surgery. Design: Prospectively randomized, blinded study. Setting: Operating room and intensive care unit of a large, urban, academic medical center. Patients: Twenty-eight patients undergoing elective coronary artery bypass grafting (CABG) with preoperative ejection fraction of at least 40 percent gave informed consent. The study group consisted of the ten patients who had a cardiac index less than or equal to 2.5 L/min/m(2) (while receiving no inotropic medication) immediately after separation from cardiopulmonary bypass. Interventions and measurements: Study patients were randomly given a starting dose of either 5 mu g/kg/min of dobutamine (n=5) or 2 mu g/kg/min of dopexamine (n=5). During the initial 30 min following separation from bypass, dosages were titrated incrementally to maintain cardiac index greater than or equal to 3.0/L/min/m(2). Further titrations of the drug were done only if cardiac index fell below 3.0 L/min/m(2) or if sustained tachycardia occurred during the 24-h study period. Data were collected at 5- and 10- min intervals for the first 30 min after separation from bypass, hourly for the next 8 h, then every 2 h for the remainder of the study period. Results: Both drugs increased cardiac index by more than 50 percent over baseline (dobutamine 2.2 +/- 0.1 to 3.5 +/- 0.2 [p<0.05]; dopexamine, 2.3 +/- 0.1 to 3.5 +/- 0.1 [p<0.05] L/min/m(2). The mean dose required to maintain cardiac index greater than or equal to 3.0L/min/m(2) was 1.5 mu g/kg/min for dopexamine and 3.5 mu g/kg/min for dobutamine. There were no significant differences in either urinary output or net sodium excretion in the dopexamine group compared with the dobutamine group, and tachycardia (heart rate >120 beats/min) was more common in the dopexamine group. Conclusions: Our study demonstrates that dopexamine produces hemodynamic, diuretic, and natriuretic effects similar to dobutamine in patients with reduced cardiac index following CABG.
引用
收藏
页码:835 / 841
页数:7
相关论文
共 47 条
  • [1] BASS AS, 1990, J PHARMACOL EXP THER, V253, P798
  • [2] SYSTEMIC AND MUSCLE OXYGEN-UPTAKE DELIVERY AFTER DOPEXAMINE INFUSION IN ENDOTOXIC DOGS
    BREDLE, DL
    CAIN, SM
    [J]. CRITICAL CARE MEDICINE, 1991, 19 (02) : 198 - 204
  • [3] ACUTE MYOCARDIAL DYSFUNCTION AND RECOVERY - A COMMON OCCURRENCE AFTER CORONARY-BYPASS SURGERY
    BREISBLATT, WM
    STEIN, KL
    WOLFE, CJ
    FOLLANSBEE, WP
    CAPOZZI, J
    ARMITAGE, JM
    HARDESTY, RL
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1990, 15 (06) : 1261 - 1269
  • [4] THE BETA-ADRENERGIC-RECEPTOR ADENYLATE-CYCLASE COMPLEX AS A TARGET FOR THERAPEUTIC INTERVENTION IN HEART-FAILURE
    BRISTOW, MR
    PORT, JD
    HERSHBERGER, RE
    GILBERT, EM
    FELDMAN, AM
    [J]. EUROPEAN HEART JOURNAL, 1989, 10 : 45 - 54
  • [5] BRISTOW MR, 1990, CIRCULATION, V82, P12
  • [6] THE ADRENERGIC NERVOUS-SYSTEM IN HEART-FAILURE
    BRISTOW, MR
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1984, 311 (13) : 850 - 851
  • [7] REGIONAL DISTRIBUTION OF BETA-ADRENOCEPTORS IN THE HUMAN-HEART - COEXISTENCE OF FUNCTIONAL BETA-1-ADRENOCEPTOR AND BETA-2-ADRENOCEPTOR IN BOTH ATRIA AND VENTRICLES IN SEVERE CONGESTIVE CARDIOMYOPATHY
    BRODDE, OE
    SCHULER, S
    KRETSCH, R
    BRINKMANN, M
    BORST, HG
    HETZER, R
    REIDEMEISTER, JC
    WARNECKE, H
    ZERKOWSKI, HR
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1986, 8 (06) : 1235 - 1242
  • [8] DRUG-INDUCED AND DISEASE-INDUCED CHANGES OF HUMAN CARDIAC BETA-1-ADRENOCEPTOR AND BETA-2-ADRENOCEPTOR
    BRODDE, OE
    ZERKOWSKI, HR
    BORST, HG
    MAIER, W
    MICHEL, MC
    [J]. EUROPEAN HEART JOURNAL, 1989, 10 : 38 - 44
  • [9] COEXISTENCE OF BETA-1-ADRENOCEPTORS AND BETA-2-ADRENOCEPTORS IN HUMAN RIGHT ATRIUM - DIRECT IDENTIFICATION BY (+/-)-[I-125]IODOCYANOPINDOLOL BINDING
    BRODDE, OE
    KARAD, K
    ZERKOWSKI, HR
    ROHM, N
    REIDEMEISTER, JC
    [J]. CIRCULATION RESEARCH, 1983, 53 (06) : 752 - 758
  • [10] DOPEXAMINE - A NOVEL AGONIST AT PERIPHERAL DOPAMINE-RECEPTORS AND BETA-2-ADRENOCEPTORS
    BROWN, RA
    DIXON, J
    FARMER, JB
    HALL, JC
    HUMPHRIES, RG
    INCE, F
    OCONNOR, SE
    SIMPSON, WT
    SMITH, GW
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1985, 85 (03) : 599 - 608